Sanofi terminated mRNA COVID-19 vaccine development to focus on recombinant vaccine candidate
On Sept. 28, 2021, Sanofi announced that it had terminated plans for its own mRNA-based COVID-19 vaccine given the success of BioNTech-Pfizer and Moderna in fighting the pandemic.
Sanofi will instead focus on another COVID-19 vaccine candidate using the protein-based approach.
Tags:
Source: Reuters
Credit:
